Industry

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell’s deep expertise and track record. LONDON & NEW YORK–(BUSINESS WIRE)–ViroCell Biologics (“ViroCell”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–#IRConference–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. BTIG, a global financial services firm specializing in investment banking, institutional trading, research … [Read more…]

New product covers cancer, heart attack, stroke, and more DES MOINES, Iowa–(BUSINESS WIRE)–Wellabe has launched a new Critical Illness insurance product in 14 states1 to protect the well-being of customers when they suffer from cancer, heart attack, stroke, or other critical illnesses. Underwritten by Medico® Insurance Company, Wellabe’s Critical Illness insurance provides customizable coverage for … [Read more…]

EVANSTON, Ill.–(BUSINESS WIRE)–Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical … [Read more…]

With 128 winners transforming 400 million lives around the world, the Prize continues to attract the world’s most pioneering sustainability solutions. 30% surge in global entries highlights the Prize’s growing impact in advancing transformative solutions across health, food, water, energy, and climate action. AI-powered solutions, disruptive innovations, and technologies that expand access to essential services … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) – Global Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million … [Read more…]

DALLAS–(BUSINESS WIRE)–HealthMark Group (“HealthMark” or “the Company”), a leading provider of clinical information exchange solutions for healthcare providers, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. This partnership aims to accelerate HealthMark’s growth as the Company advances its mission to optimize the exchange of healthcare data through … [Read more…]

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union OSAKA, Japan & WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), … [Read more…]

BEIJING–(BUSINESS WIRE)–#AntibodyDiscovery–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full … [Read more…]

– Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer’s disease featured, with initiation planned in 2025 – – Plans … [Read more…]